Methylphenidate: yearly treatment review advised

Updated guidance from the MHRA advises that treatment with methylphenidate should be interrupted at least yearly to determine whether continued use is necessary.

The MHRA has also reminded healthcare professionals of the need to screen and monitor patients for psychiatric and cardiovascular symptoms before and during treatment with the stimulant.

 

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more